Kimia Farma Persero Stock Fundamentals

KAEF Stock  IDR 610.00  10.00  1.67%   
Kimia Farma Persero fundamentals help investors to digest information that contributes to Kimia Farma's financial success or failures. It also enables traders to predict the movement of Kimia Stock. The fundamental analysis module provides a way to measure Kimia Farma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kimia Farma stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Kimia Farma Persero Company Return On Asset Analysis

Kimia Farma's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Return On Asset

 = 

Net Income

Total Assets

More About Return On Asset | All Equity Analysis

Current Kimia Farma Return On Asset

    
  0.0089  
Most of Kimia Farma's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kimia Farma Persero is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Competition

Based on the latest financial disclosure, Kimia Farma Persero has a Return On Asset of 0.0089. This is 100.1% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The return on asset for all Indonesia stocks is 106.36% lower than that of the firm.

Kimia Farma Persero Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Kimia Farma's current stock value. Our valuation model uses many indicators to compare Kimia Farma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kimia Farma competition to find correlations between indicators driving Kimia Farma's intrinsic value. More Info.
Kimia Farma Persero is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kimia Farma's earnings, one of the primary drivers of an investment's value.

Kimia Return On Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kimia Farma's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kimia Farma could also be used in its relative valuation, which is a method of valuing Kimia Farma by comparing valuation metrics of similar companies.
Kimia Farma is currently under evaluation in return on asset category among its peers.

Kimia Fundamentals

About Kimia Farma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Kimia Farma Persero's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kimia Farma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kimia Farma Persero based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
PT Kimia Farma Tbk produces and sells medicines, herbal medicines, iodine, salts, quinine and their derivative products, and vegetable oils in Indonesia, rest of Asia, Europe, Australia, Africa, and New Zealand. The company was founded in 1817 and is headquartered in Jakarta, Indonesia. Kimia Farma operates under Drug ManufacturersSpecialty Generic classification in Indonesia and is traded on Jakarta Stock Exchange. It employs 11772 people.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Other Information on Investing in Kimia Stock

Kimia Farma financial ratios help investors to determine whether Kimia Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kimia with respect to the benefits of owning Kimia Farma security.